A Phase 2 Multiple Ascending Dose Trial of Bapineuzumab in Mild to Moderate Alzheimer Disease

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M and Bapineuzumab 201 Clinical Trial Investigators (2009). A phase 2 multiple ascending dose trial of Bapineuzumab in mild to moderate Alzheimer disease. Neurology; 73:  2052-2053. PMCID:  2790221.